drugset / Trial / NCT04719481

Pravastatin Reduces Acute Phase Response of Zoledronic Acid

NCT04719481

Phase 4 Unknown 110 enrolled Peking University Third Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Acute phase response (APR) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. It's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl pyrophosphate (IPP) accumulation. And the latter can active γδT cells in the circulation, resulting in inflammatory cytokine release. Statins can inhibit the conversion of HMG-CoA to mevalonate that may reduce the accumulation of IPP. Therefore, it is possible that statins can be taken in advance to reduce APR caused by zoledronic acid infusion.

Timeline

Start
2021-11
Primary completion
2021-11
Completion
2022-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule 80 mg Oral